Answers are grounded in this paper and cite their sources.
Despite recent therapeutic advances, the outcomes of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) remain poor, and novel therapies are needed. 1,2Bcl-2 and Bcl-xL are highly expressed in ALL, and pharmacologic inhibition of these proteins has antileukemic activity in preclinical studies. [3][4]4][5][6][7][8][9] Venetoclax-based regimens have been studied in ALL in small prospective trials, with promising results. [10][11]1][12] Because upregulation of Bcl-xL is an established resistance mechanism to venetoclax, we hypothesized that adding the dual Bcl-2/Bcl-xL inhibitor navitoclax to this regimen may further improve outcomes.Adult patients with relapsed/refractory Philadelphia chromosome-negative ALL who had not previously received venetoclax were eligible for this phase 1/2 study of mini-hyper-cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate and cytarabine (CVD) in combination with venetoclax and navitoclax.The study protocol, including the complete inclusion/exclusion criteria, are detailed in the supplemental Protocol.Patients received the mini-hyper-CVD regimen at doses that have been previous reported. 13In cycle 1, patients received venetoclax with ramp-up to a maximum dose of 200 to 400 mg on days 1 to 21.For cycles 2 to 8, patients received venetoclax at the assigned dose on days 1 to 7. Navitoclax 50 mg daily was given on days 1 to 21 of cycle 1 and on days 1 to 7 of cycles 2 to 8.This dose was selected based on previously published data. 14A bone marrow assessment was performed on cycle 1, day 14, and venetoclax and navitoclax were held for patients who achieved a marrow remission.Cycles were administered every 28 days.Patients with T-cell ALL also received additional cycles of nelarabine and PEGylated (PEG)-asparaginase, given in cycles 4N and 5N (intercalated after cycles 4 and 5, respectively), as previously reported. 10The full treatment schema is detailed in the protocol in the supplemental Protocol.This study was registered at ClinicalTrials.gov as NCT03808610.
No takes yet. Share an insight, caveat, or question.
Short et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: